Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia.
Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels.
Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia who do not respond adequately to diet.
Prevention of cardiovascular events: To reduce the risk of myocardial infarctionIn adult patients without clinically evident coronary heart disease, but with at least 3 risk factors for coronary heart disease such as age over 55, men, smoking, type 2 diabetes, left ventricular hypertrophy, specific abnormalities on the electrocardiogram, proteinuria, low HDL-C ? 6, or a family history of early coronary heart disease.
Pediatrics (10-17 years): Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
a. LDL-C remains ? 190 mg/dL or
b. LDL-C remains ? 160 mg/dL and:
• there is a positive family history of premature cardiovascular disease or
• two or more other CVD risk factors are present in the pediatric patient

This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: C
Dosage form: Film coated tablet
Packaging: 10's x 10, 7's x 4
Therapeutic area: Active pharmaceutical ingredient: